Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo

Cancer Research

Volumn 65, Issue 5, 2005, Pages 2009-2017

  Sanchez Perez, Luis ^a,b   Kottke, Timothy ^a   Diaz, Rosa Maria ^a,b   Ahmed, Atique ^a   Thompson, Jill ^a   Chong, Heung ^c   Melcher, Alan ^d   Holmen, Sheri ^e   Daniels, Gregory ^a   Vile, Richard G ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIGEN; AZACITIDINE; GANCICLOVIR; GLYCOPROTEIN GP 100; HEAT SHOCK PROTEIN 70; MONOPHENOL MONOOXYGENASE; PLASMID DNA; THYMIDINE KINASE; TYROSINASE RELATED PROTEIN 2; VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGENIC VARIATION; ARTICLE; CELL CULTURE; CELL KILLING; CONTROLLED STUDY; GENETIC TRANSCRIPTION; INFLAMMATION; MELANOCYTE; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRESSURE; PRIORITY JOURNAL; SUICIDE GENE; T LYMPHOCYTE; TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DNA METHYLATION; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTRAMOLECULAR OXIDOREDUCTASES; MELANOCYTES; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, NUDE; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; PORE FORMING CYTOTOXIC PROTEINS; TUMOR ESCAPE; VACCINATION; VACCINES, DNA;

EID: 20144387910     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3216     Document Type: Article

References (59)

1. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 2002;188:136-46.
2. + T cells. J Exp Med 2003;198:569-80.
3. Bronte V, Apolloni E, Ronca R, et al. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000;60:253-8.
4. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-38.
5. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
6. Hodi FS, Mihm MC, Soiffer RJ. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712-7.
7. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.
8. Parmiani G. Tumor immunity as autoimmunity: tumor antigens include normal self-proteins which stimulate anergic peripheral T cells. Immunol Today 1993;14:536-8.
9. Pardoll DM. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A 1999;96:5340-2.
10. Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole IC. A symbiotic concept of autoimmunity and tumor immunity: lessons from vitiligo. Trends Immunol 2001;22:130-6.
11. Daniels G, Sanchez-Perez L, Kottke T, et al. Intentional killing of normal melanocytes by gene transfer generates curative anti melanoma without obligate autoimmunity. Nat Biotechnol 2004;22:1125-32.
12. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1994;1:279-87.
13. Melcher AA, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998;4:581-7.
14. Todryk S, Melcher AA, Hardwick N, et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999;163:1398-408.
15. Gough MJ, Melcher AA, Ahmed A, et al. Macrophages orchestrate the immune response to tumor cell death. Cancer Res 2001;61:7240-7.
16. Srivastava PK. Hypothesis: controlled necrosis as a tool for immunotherapy of human cancer. Cancer Immun 2003;3:4.
17. Restifo NP. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol 2000;12:597-603.
18. Millar DG, Garza KM, Odermatt B, et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med 2003;9:1469-76.
19. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435-42.
20. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277:15028-34.
21. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14:303-13.
22. Srivastava P, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994;39:93-8.
23. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117-20.
24. Walker LSK, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2002;2:11-9.
25. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
26. Linardakis E, Bateman A, Phan V, et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 2002;62:5495-504.
27. Ganss R, Montoliu L, Monaghan AP, Schutz GA. Cell-specific enhancer far upstream of the mouse tyrosinase gene confers high level and copy number-related expression in transgenic mice. EMBO J 1994;13:3083-93.
28. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993;53:962-7.
29. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993;53:3860-4.
30. Diaz RM, Todryk S, Chong H, et al. Rapid adenoviral transduction of freshly resected tumor explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. Gene Ther 1998;5:869-79.
31. Vile RG, Castleden SC, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Int J Cancer 1997;71:267-74.
32. Bonnotte B, Gough M, Phan V, et al. Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells. Cancer Res 2003;63:2145-9.
33. Altman DG. Analysis of survival times. In: Practical statistics for medical research; 1991. p. 365-95.
34. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:1553-61.
35. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185:453-9.
36. Syzyf M. Targeting DNA methyltransferase in cancer. Cancer Metastasis Rev 1998;17:219-31.
37. Jutterman R, Li E, Jeaenisch R. Toxicity of 5-aza-2-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 1994;91:11797-801.
38. Riley PA. Melanogenesis: a realistic target for anti-melanoma therapy? Eur J Cancer 1991;27:1172-7.
39. Wick M, Dubey P, Koeppen H, et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997;186:229-38.
40. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994;12:991-1045.
41. Speiser DE, Miranda R, Zakarian A, et al. Self-antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 1997;186:645-53.
42. Staveley-O'Carroll K, Sotomayor EM, Montgomery J, et al. Induction of antigen specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83.
43. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002;196:1091-7.
44. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells [Comment]. J Exp Med 2000;191:411-6.
45. Mougneau E, Hugues S, Glaichenhaus N. Antigen presentation by dendritic cells in vivo. J Exp Med 2002;196:1013-6.
46. Spiotto MT, Yu P, Roewley DA, et al. Increasing tumor antigen expression overcomes ignorance to solid tumors via cross-presentation by bone marrow-derived stromal cells. Immunity 2002;17:737-47.
47. Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999;96:2233-8.
48. Ochsenbein AF, Sierra S, Odermatt B, et al. Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
49. Spiotto MT, Fu YX, Schreiber H. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol 2003;15:725-30.
50. Zheng P, Guo Y, Niu Q, et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998;396:373-6.
51. Seliger B, Maeurer MJ, Ferrone S. TAP off-tumors on. Immunol Today 1997;18:292-9.
52. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000;21:455-64.
53. Bai XF, Liu J, Li O, Zheng P, Liu Y. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 2003;111:1487-96.
54. + T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 2003;33:556-66.
55. Lollini PL, Forni G. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol 2003;24:62-6.
56. Douawho CK, Pride MW, Kripke ML. Persistence of immunogenic pulmonary metastases in the presence of protective anti-melanoma immunity. Cancer Res 2001;61:215-21.
57. Serrano A, Tanzarella S, Lionello I, et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 2001;94:243-51.
58. Kaminski R, Kozar K, Niderla J, et al. Demethylating agent 5-aza-2′-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo. Oncol Rep 2004;12:509-16.
59. Creagan ET, Schaid DJ, Hartman LC, Loprinzi CL. A phase 11 study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma. Am J Clin Oncol 1993;16:243-4.